Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Microbiology

2015

Pseudomonas aeruginosa

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

Cyclic Di-Gmp-Mediated Repression Of Swarming Motility By Pseudomonas Aeruginosa Pa14 Requires The Motab Stator, S. L. Kuchma, N. J. Delalez, L. M. Filkins, E. A. Snavely, J. P. Armitage, G. A. O'Toole Oct 2015

Cyclic Di-Gmp-Mediated Repression Of Swarming Motility By Pseudomonas Aeruginosa Pa14 Requires The Motab Stator, S. L. Kuchma, N. J. Delalez, L. M. Filkins, E. A. Snavely, J. P. Armitage, G. A. O'Toole

Dartmouth Scholarship

The second messenger cyclic diguanylate (c-di-GMP) plays a critical role in the regulation of motility. In Pseudomonas aeruginosa PA14, c-di-GMP inversely controls biofilm formation and surface swarming motility, with high levels of this dinucleotide signal stimulating biofilm formation and repressing swarming. P. aeruginosa encodes two stator complexes, MotAB and MotCD, that participate in the function of its single polar flagellum. Here we show that the repression of swarming motility requires a functional MotAB stator complex. Mutating the motAB genes restores swarming motility to a strain with artificially elevated levels of c-di-GMP as well as stimulates swarming in the wild-type strain, …


Antibiogram Of Multidrug-Resistant Isolates Of Pseudomonas Aeruginosa After Biofield Treatment, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana Oct 2015

Antibiogram Of Multidrug-Resistant Isolates Of Pseudomonas Aeruginosa After Biofield Treatment, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana

Mahendra Kumar Trivedi

In recent years, prevalence of multidrug resistance (MDR) in Pseudomonas aeruginosa (P. aeruginosa) has been noticed with high morbidity and mortality. Aim of the present study was to determine the impact of Mr. Trivedi’s biofield treatment on MDR clinical lab isolates (LS) of P. aeruginosa. Five MDR clinical lab isolates (LS 22, LS 23, LS 38, LS 47, and LS 58) of P. aeruginosa were taken and divided into two groups i.e. control and biofield treated. Control and treated group were analyzed for antimicrobial susceptibility pattern, minimum inhibitory concentration (MIC), biochemical study and biotype number using MicroScan Walk-Away® system. The …